New treatment options
Various new glaucoma medications were introduced in the 1990s (3, 4). In the 20 years that followed, few advancements were made in treatment, other than the introduction of preservative-free eye drops.
In the last five years, however, considerable developments have been seen in glaucoma surgery (4).
For many years, trabeculectomy has been the most common method, which involves using surgical instruments to create a new drainage route for the aqueous humour outside the trabecular meshwork (4). However, this method is invasive and is associated with some risk of complications and lengthy postoperative follow-up. Nevertheless, it is a well-documented treatment with the potential for very good outcomes.
This method is invasive and is associated with some risk of complications and lengthy postoperative follow-up
In recent years, a number of new stents and shunts have been introduced that are implanted in the anterior part of the eye to drain the aqueous humour and lower the pressure. The generic term for this type of treatment is micro-invasive/minimally invasive glaucoma surgery (MIGS). This new health technology has attracted a lot of attention and positive publicity. Clinical testing and documentation have, however, been limited, and in parallel with the publication of new clinical results, the euphoria has subsided slightly. However, MIGS still seems to have a place in glaucoma treatment and is potentially suitable for a wide range of patients. Extensive research is nevertheless needed, and long-term results over several years need to be examined and presented.